<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="163101">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01822496</url>
  </required_header>
  <id_info>
    <org_study_id>NCI-2013-00737</org_study_id>
    <secondary_id>NCI-2013-00737</secondary_id>
    <secondary_id>RTOG 1306</secondary_id>
    <secondary_id>RTOG-1306</secondary_id>
    <secondary_id>U10CA021661</secondary_id>
    <nct_id>NCT01822496</nct_id>
  </id_info>
  <brief_title>Erlotinib Hydrochloride or Crizotinib and Chemoradiation Therapy in Treating Patients With Stage III Non-Small Cell Lung Cancer</brief_title>
  <official_title>A Randomized Phase II Study of Individualized Combined Modality Therapy for Stage III Non-Small Cell Lung Cancer (NSCLC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      This randomized phase II trial studies how well giving erlotinib hydrochloride or crizotinib
      and chemoradiation therapy works in treating patients with stage III non-small cell lung
      cancer. Radiation therapy uses high energy x rays to kill tumor cells. Specialized radiation
      therapy that delivers a high dose of radiation directly to the tumor may kill more tumor
      cells and cause less damage to normal tissue. Drugs used in chemotherapy, such as cisplatin,
      etoposide, paclitaxel, and carboplatin, work in different ways to stop the growth of tumor
      cells, either by killing the cells or by stopping them from dividing. It is not yet known
      whether giving erlotinib hydrochloride is more effective than crizotinib with chemoradiation
      therapy in treating patients with non-small cell lung cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. To assess whether patients with unresectable local-regionally advanced non-small cell
      lung cancer (NSCLC) treated with targeted agents based on molecular characteristics have a
      longer progression-free survival than those treated with standard care therapy alone.

      SECONDARY OBJECTIVES:

      I. To evaluate response rate. II. To assess toxicity. III. To assess overall survival. IV.
      To correlate clinical outcomes with tumor molecular aberrations identified from deep
      sequencing of selected kinomes in patients from whom adequate baseline tissue is available.

      OUTLINE: Patients are randomized to 1 of 4 treatment arms. Patients are stratified according
      to mutation status.

      CHEMORADIATION: In all treatment arms, patients undergo concurrent intensity modulated
      radiation therapy (IMRT) or 3-dimensional conformal radiation therapy (3-D CRT) once daily
      (QD) 5 days a week for 6 weeks. Patients receive 1 of 2 chemotherapy regimens based on the
      discretion of the treating physician. Patients receive cisplatin intravenously (IV) over 1-2
      hours on days 1, 8, 29, and 36 and etoposide IV over 1 hour on days 1-5 and 29-33. Treatment
      repeats every 4 weeks for up to 2 courses in the absence of disease progression or
      unacceptable toxicity. Some patients receive paclitaxel IV on days 1, 8, 15, 22, 29, and 36
      and carboplatin IV weekly during radiation therapy for 6 weeks. Two courses of consolidation
      treatment will begin 4-6 weeks after completion of radiation therapy with paclitaxel IV on
      days 1 and 22 and carboplatin IV on days 1 and 22 in the absence of disease progression or
      unacceptable toxicity.

      ARM I (induction therapy): Patients receive erlotinib hydrochloride orally (PO) QD for up to
      12 weeks. Patients achieving disease progression after 6 weeks undergo concurrent
      chemoradiation therapy.

      ARM III (induction therapy): Patients receive crizotinib PO twice daily (BID) for up to 12
      weeks. Patients achieving disease progression after 6 weeks undergo concurrent
      chemoradiation therapy.

      ARMS II AND IV (concurrent chemoradiation): Patients receive concurrent chemotherapy with
      thoracic radiation therapy beginning on day 1. Treatment continues in the absence of disease
      progression or unacceptable toxicity.

      After completion of study treatment, patients are followed up at 1 month, every 3 months for
      2 years, every 6 months for 3 years and then yearly thereafter.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2013</start_date>
  <primary_completion_date type="Anticipated">March 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>Occurrence of local or regional progression, distant metastases, or death from any cause from the time of randomization to the occurrence of one of the failure events, whichever occurs first, assessed up to 12 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>The product limit estimator developed by Kaplan and Meier will be used. Their 95% confidence intervals will be estimated. Comparisons between arms will be conducted using a log rank test.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients who respond (completely or partially) to each treatment, assessed by the Response Evaluation Criteria in Solid Tumors (RECIST)</measure>
    <time_frame>Up to 10 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>Estimated as well as their 95% confidence intervals. Tested using Fisher's exact test and using a logistic regression model to incorporate other prognostic covariates.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of grade 3-5 adverse events, graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v4.0</measure>
    <time_frame>Up to 10 years</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Summarized using frequency table methods.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>Time to death from any cause, assessed up to 12 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>The product limit estimator developed by Kaplan and Meier will be used. Their 95% confidence intervals will be estimated. Comparisons between arms will be conducted using a log rank test.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Local-regional progression free survival</measure>
    <time_frame>Time from randomization to local-regional progression or death, whichever comes first, assessed up to 10 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>Appropriate methods for competing risks will be applied, specifically cumulative incidence functions for estimation of cumulative cause specific event probabilities with associated testing for differences, and regression methods for cause-specific hazards and subdistribution hazards underlying cumulative incidence functions may be applied accordingly for exploratory purposes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Distant progression free survival</measure>
    <time_frame>Time from randomization to distant progression or death, whichever occurs first, assessed up to 10 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>Appropriate methods for competing risks will be applied, specifically cumulative incidence functions for estimation of cumulative cause specific event probabilities with associated testing for differences, and regression methods for cause-specific hazards and subdistribution hazards underlying cumulative incidence functions may be applied accordingly for exploratory purposes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Deep sequencing of selected kinomes in patients from whom adequate baseline tissue is available</measure>
    <time_frame>Up to 10 years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">234</enrollment>
  <condition>Stage IIIA Non-small Cell Lung Cancer</condition>
  <condition>Stage IIIB Non-small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Arm I (erlotinib hydrochloride, concurrent chemoradiation)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive erlotinib hydrochloride PO QD for up to 12 weeks. Patients achieving disease progression after 6 weeks undergo concurrent chemoradiation therapy. CHEMORADIATION: In all treatment arms, patients undergo concurrent IMRT or 3-D CRT QD 5 days a week for 6 weeks. Patients receive 1 of 2 chemotherapy regimens based on the discretion of the treating physician. Patients receive cisplatin IV over 1-2 hours on days 1, 8, 29, and 36 and etoposide IV over 1 hour on days 1-5 and 29-33. Treatment repeats every 4 weeks for up to 2 courses in the absence of disease progression or unacceptable toxicity. Some patients receive paclitaxel IV on days 1, 8, 15, 22, 29, and 36 and carboplatin IV weekly during radiation therapy for 6 weeks. Two courses of consolidation treatment will begin 4-6 weeks after completion of radiation therapy with paclitaxel IV on days 1 and 22 and carboplatin IV on days 1 and 22 in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm III (crizotinib, concurrent chemoradiation)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive crizotinib PO BID for up to 12 weeks. Patients achieving disease progression after 6 weeks undergo concurrent chemoradiation therapy. CHEMORADIATION: In all treatment arms, patients undergo concurrent IMRT or 3-D CRT QD 5 days a week for 6 weeks. Patients receive 1 of 2 chemotherapy regimens based on the discretion of the treating physician. Patients receive cisplatin IV over 1-2 hours on days 1, 8, 29, and 36 and etoposide IV over 1 hour on days 1-5 and 29-33. Treatment repeats every 4 weeks for up to 2 courses in the absence of disease progression or unacceptable toxicity. Some patients receive paclitaxel IV on days 1, 8, 15, 22, 29, and 36 and carboplatin IV weekly during radiation therapy for 6 weeks. Two courses of consolidation treatment will begin 4-6 weeks after completion of radiation therapy with paclitaxel IV on days 1 and 22 and carboplatin IV on days 1 and 22 in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm II (chemoradiation, EGFR TK Mutation Cohort)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients receive concurrent chemotherapy with thoracic radiation therapy beginning on day 1. Treatment continues in the absence of disease progression or unacceptable toxicity. CHEMORADIATION: In all treatment arms, patients undergo concurrent IMRT or 3-D CRT QD 5 days a week for 6 weeks. Patients receive 1 of 2 chemotherapy regimens based on the discretion of the treating physician. Patients receive cisplatin IV over 1-2 hours on days 1, 8, 29, and 36 and etoposide IV over 1 hour on days 1-5 and 29-33. Treatment repeats every 4 weeks for up to 2 courses in the absence of disease progression or unacceptable toxicity. Some patients receive paclitaxel IV on days 1, 8, 15, 22, 29, and 36 and carboplatin IV weekly during radiation therapy for 6 weeks. Two courses of consolidation treatment will begin 4-6 weeks after completion of radiation therapy with paclitaxel IV on days 1 and 22 and carboplatin IV on days 1 and 22 in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm IV (chemoradiation, ALK Tran L Cohort)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients receive concurrent chemotherapy with thoracic radiation therapy beginning on day 1. Treatment continues in the absence of disease progression or unacceptable toxicity. CHEMORADIATION: In all treatment arms, patients undergo concurrent IMRT or 3-D CRT QD 5 days a week for 6 weeks. Patients receive 1 of 2 chemotherapy regimens based on the discretion of the treating physician. Patients receive cisplatin IV over 1-2 hours on days 1, 8, 29, and 36 and etoposide IV over 1 hour on days 1-5 and 29-33. Treatment repeats every 4 weeks for up to 2 courses in the absence of disease progression or unacceptable toxicity. Some patients receive paclitaxel IV on days 1, 8, 15, 22, 29, and 36 and carboplatin IV weekly during radiation therapy for 6 weeks. Two courses of consolidation treatment will begin 4-6 weeks after completion of radiation therapy with paclitaxel IV on days 1 and 22 and carboplatin IV on days 1 and 22 in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cisplatin</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm I (erlotinib hydrochloride, concurrent chemoradiation)</arm_group_label>
    <arm_group_label>Arm III (crizotinib, concurrent chemoradiation)</arm_group_label>
    <arm_group_label>Arm II (chemoradiation, EGFR TK Mutation Cohort)</arm_group_label>
    <arm_group_label>Arm IV (chemoradiation, ALK Tran L Cohort)</arm_group_label>
    <other_name>CACP</other_name>
    <other_name>CDDP</other_name>
    <other_name>CPDD</other_name>
    <other_name>DDP</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>etoposide</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm I (erlotinib hydrochloride, concurrent chemoradiation)</arm_group_label>
    <arm_group_label>Arm III (crizotinib, concurrent chemoradiation)</arm_group_label>
    <arm_group_label>Arm II (chemoradiation, EGFR TK Mutation Cohort)</arm_group_label>
    <arm_group_label>Arm IV (chemoradiation, ALK Tran L Cohort)</arm_group_label>
    <other_name>EPEG</other_name>
    <other_name>VP-16</other_name>
    <other_name>VP-16-213</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>paclitaxel</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm I (erlotinib hydrochloride, concurrent chemoradiation)</arm_group_label>
    <arm_group_label>Arm III (crizotinib, concurrent chemoradiation)</arm_group_label>
    <arm_group_label>Arm II (chemoradiation, EGFR TK Mutation Cohort)</arm_group_label>
    <arm_group_label>Arm IV (chemoradiation, ALK Tran L Cohort)</arm_group_label>
    <other_name>Anzatax</other_name>
    <other_name>Asotax</other_name>
    <other_name>TAX</other_name>
    <other_name>Taxol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>carboplatin</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm I (erlotinib hydrochloride, concurrent chemoradiation)</arm_group_label>
    <arm_group_label>Arm III (crizotinib, concurrent chemoradiation)</arm_group_label>
    <arm_group_label>Arm II (chemoradiation, EGFR TK Mutation Cohort)</arm_group_label>
    <arm_group_label>Arm IV (chemoradiation, ALK Tran L Cohort)</arm_group_label>
    <other_name>Carboplat</other_name>
    <other_name>CBDCA</other_name>
    <other_name>JM-8</other_name>
    <other_name>Paraplat</other_name>
    <other_name>Paraplatin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>erlotinib hydrochloride</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Arm I (erlotinib hydrochloride, concurrent chemoradiation)</arm_group_label>
    <other_name>CP-358,774</other_name>
    <other_name>erlotinib</other_name>
    <other_name>OSI-774</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>crizotinib</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Arm III (crizotinib, concurrent chemoradiation)</arm_group_label>
    <other_name>c-met/hepatocyte growth factor receptor tyrosine kinase inhibitor PF-02341066</other_name>
    <other_name>c-met/HGFR tyrosine kinase inhibitor PF-02341066</other_name>
    <other_name>MET Tyrosine Kinase Inhibitor PF-02341066</other_name>
    <other_name>PF-02341066</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>intensity-modulated radiation therapy</intervention_name>
    <description>Undergo IMRT</description>
    <arm_group_label>Arm I (erlotinib hydrochloride, concurrent chemoradiation)</arm_group_label>
    <arm_group_label>Arm III (crizotinib, concurrent chemoradiation)</arm_group_label>
    <arm_group_label>Arm II (chemoradiation, EGFR TK Mutation Cohort)</arm_group_label>
    <arm_group_label>Arm IV (chemoradiation, ALK Tran L Cohort)</arm_group_label>
    <other_name>IMRT</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>3-dimensional conformal radiation therapy</intervention_name>
    <description>Undergo 3-D CRT</description>
    <arm_group_label>Arm I (erlotinib hydrochloride, concurrent chemoradiation)</arm_group_label>
    <arm_group_label>Arm III (crizotinib, concurrent chemoradiation)</arm_group_label>
    <arm_group_label>Arm II (chemoradiation, EGFR TK Mutation Cohort)</arm_group_label>
    <arm_group_label>Arm IV (chemoradiation, ALK Tran L Cohort)</arm_group_label>
    <other_name>3D conformal radiation therapy</other_name>
    <other_name>3D-CRT</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>diagnostic laboratory biomarker analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Arm I (erlotinib hydrochloride, concurrent chemoradiation)</arm_group_label>
    <arm_group_label>Arm III (crizotinib, concurrent chemoradiation)</arm_group_label>
    <arm_group_label>Arm II (chemoradiation, EGFR TK Mutation Cohort)</arm_group_label>
    <arm_group_label>Arm IV (chemoradiation, ALK Tran L Cohort)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically or cytologically confirmed, newly diagnosed non-squamous NSCLC

          -  Unresectable stage IIIA or IIIB disease; patients must be surgically staged to
             confirm N2 or N3 disease; patients may have invasive mediastinal staging by
             mediastinoscopy, mediastinotomy, endobronchial ultrasound transbronchial aspiration
             (EBUS-TBNA), endoscopic ultrasound (EUS), or video-assisted thoracoscopic surgery
             (VATS) within 30 days prior to registration

          -  Patients with any T with N2 or N3 are eligible; patients with T3, N1-N3 disease are
             eligible if deemed unresectable; patients with T4, any N are eligible

          -  Patients must have measurable disease, i.e., lesions that can be accurately measured
             in at least 1 dimension (longest dimension in the plane of measurement is to be
             recorded) with a minimum size of 10 mm by computed tomography (CT) scan (CT scan
             slice thickness no greater than 5 mm); tumor measurements must be taken within 42
             days prior to registration

          -  Patients with a pleural effusion, which is a transudate, cytologically negative and
             non-bloody, are eligible if the radiation oncologist feels the tumor can be
             encompassed within a reasonable field of radiotherapy

          -  If a pleural effusion can be seen on the chest CT but not on chest x-ray and is too
             small to tap, the patient will be eligible; patients who develop a new pleural
             effusion after thoracotomy or other invasive thoracic procedure will be eligible

          -  The institution's pre-enrollment biomarker screening at a Clinical Laboratory
             Improvement Amendments (CLIA) certified lab documents presence of known &quot;sensitive&quot;
             mutations in epidermal growth factor receptor tyrosine kinase (EGFR TK) domain (exon
             19 deletion, L858) and EML4-anaplastic lymphoma kinase (ALK) fusion arrangement;
             either the primary tumor or the metastatic lymph node tissue may be used for testing
             of mutations

          -  The institution's pre-enrollment biomarker screening at a CLIA certified lab
             documents absence of T790M mutation in the EGFR TK domain

          -  Appropriate stage for protocol entry, including no distant metastases, based upon the
             following minimum diagnostic workup:

               -  History/physical examination, including recording of pulse, blood pressure (BP),
                  weight, and body surface area, within 45 days prior to registration

               -  Whole body fludeoxyglucose-positron emission tomography (FDG-PET)/CT (orbits to
                  mid-thighs) within 30 days prior to registration; PET/CT must be negative for
                  distant metastasis

               -  CT scan of the chest with contrast (unless medically contraindicated) within 30
                  days prior to registration;

               -  Magnetic resonance imaging (MRI) of the brain with contrast (or CT scan with
                  contrast, if MRI medically contraindicated) within 30 days prior to registration

          -  Zubrod performance status 0-1 within 14 days prior to registration

          -  Absolute neutrophil count (ANC) &gt;= 1,500 cells/mm^3

          -  Platelets &gt;= 100,000 cells/mm^3

          -  Hemoglobin &gt;= 8.0 g/dl (Note: the use of transfusion or other intervention to achieve
             hemoglobin [Hgb] &gt;= 8.0 g/dl is acceptable)

          -  Calculated creatinine clearance &gt;= 50 ml/min (by Cockroft-Gault formula) within 14
             days prior to registration

          -  Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) &lt; 3 X upper limit of
             normal (ULN) within 14 days prior to registration

          -  Bilirubin &lt; 3 X ULN within 14 days prior to registration

          -  Negative serum pregnancy test within 14 days prior to registration for women of
             childbearing potential

          -  Patient must provide study specific informed consent prior to study entry, including
             consent for mandatory screening of tissue

        Exclusion Criteria:

          -  Prior invasive malignancy (except non-melanomatous skin cancer) unless disease free
             for a minimum of 730 days (2 years) (for example, carcinoma in situ of the breast,
             oral cavity, or cervix are all permissible)

          -  Prior systemic chemotherapy for the study cancer; note that prior chemotherapy for a
             different cancer is allowable

          -  Prior radiotherapy to the region of the study cancer that would result in overlap of
             radiation therapy fields

          -  Atelectasis of the entire lung

          -  Contralateral hilar node involvement

          -  Exudative, bloody, or cytologically malignant effusions

          -  Severe, active co-morbidity, defined as follows:

               -  Unstable angina and/or congestive heart failure requiring hospitalization within
                  the last 6 months

               -  Transmural myocardial infarction within the last 6 months

               -  Acute bacterial or fungal infection requiring intravenous antibiotics at the
                  time of registration

               -  Chronic obstructive pulmonary disease exacerbation or other respiratory illness
                  requiring hospitalization or precluding study therapy at the time of
                  registration; hepatic insufficiency resulting in clinical jaundice and/or
                  coagulation defects; note, however, that laboratory tests for liver function and
                  coagulation parameters are not required for entry into this protocol

               -  Acquired immune deficiency syndrome (AIDS) based upon current Centers for
                  Disease and Control (CDC) definition; note, however, that human immunodeficiency
                  virus (HIV) testing is not required for entry into this protocol; the need to
                  exclude patients with AIDS from this protocol is necessary because the
                  treatments involved in this protocol may be significantly immunosuppressive;
                  protocol-specific requirements may also exclude immuno-compromised patients

          -  Pregnancy or women of childbearing potential and men who are sexually active and not
             willing/able to use medically acceptable forms of contraception; this exclusion is
             necessary because the treatment involved in this study may be significantly
             teratogenic

          -  Prior allergic reaction to the study drug(s) involved in this protocol
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ramaswamy Govindan</last_name>
    <role>Principal Investigator</role>
    <affiliation>Radiation Therapy Oncology Group</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Stanford University Hospitals and Clinics</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Billy W. Loo</last_name>
      <phone>650-498-7061</phone>
      <email>ccto-office@stanford.edu</email>
    </contact>
    <investigator>
      <last_name>Billy W. Loo</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Memorial Hospital Colorado Springs</name>
      <address>
        <city>Colorado Springs</city>
        <state>Colorado</state>
        <zip>80909</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jane W. Ridings</last_name>
      <phone>719-365-2406</phone>
    </contact>
    <investigator>
      <last_name>Jane W. Ridings</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Christiana Care Health System-Christiana Hospital</name>
      <address>
        <city>Newark</city>
        <state>Delaware</state>
        <zip>19718</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Adam Raben</last_name>
      <phone>302-733-6227</phone>
    </contact>
    <investigator>
      <last_name>Adam Raben</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Edna Williams Cancer Center at the Baptist Cancer Institute</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32207</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Douglas W. Johnson</last_name>
      <phone>904-202-7051</phone>
    </contact>
    <investigator>
      <last_name>Douglas W. Johnson</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cancer Specialists of North Florida-Baptist South</name>
      <address>
        <city>Jascksonville</city>
        <state>Florida</state>
        <zip>32258</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Douglas W. Johnson</last_name>
      <phone>904-202-7051</phone>
    </contact>
    <investigator>
      <last_name>Douglas W. Johnson</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UF Cancer Center at Orlando Health</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32806</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Justin Rineer</last_name>
      <phone>321-841-7246</phone>
    </contact>
    <investigator>
      <last_name>Justin Rineer</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cancer Specialists of North Florida-Putnam</name>
      <address>
        <city>Palatka</city>
        <state>Florida</state>
        <zip>32177</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Douglas W. Johnson</last_name>
      <phone>904-202-7051</phone>
    </contact>
    <investigator>
      <last_name>Douglas W. Johnson</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cancer Specialists of North Florida-Saint Augustine</name>
      <address>
        <city>Saint Augustine</city>
        <state>Florida</state>
        <zip>32086</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Douglas W. Johnson</last_name>
      <phone>904-202-7051</phone>
    </contact>
    <investigator>
      <last_name>Douglas W. Johnson</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Robert and Carol Weissman Cancer Center at Martin Health</name>
      <address>
        <city>Stuart</city>
        <state>Florida</state>
        <zip>34994</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jorge G. Castillo-Perez</last_name>
      <phone>772-288-5858ext4</phone>
    </contact>
    <investigator>
      <last_name>Jorge G. Castillo-Perez</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Emory University/Winship Cancer Institute</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kristin A. Higgins</last_name>
      <phone>404-778-1868</phone>
    </contact>
    <investigator>
      <last_name>Kristin A. Higgins</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Northeast Georgia Medical Center</name>
      <address>
        <city>Gainesville</city>
        <state>Georgia</state>
        <zip>30501</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Frank G. Lake</last_name>
      <phone>770-219-8800</phone>
      <email>cancerpatient.navigator@nghs.com</email>
    </contact>
    <investigator>
      <last_name>Frank G. Lake</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Queen's Medical Center</name>
      <address>
        <city>Honolulu</city>
        <state>Hawaii</state>
        <zip>96813</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paul A. DeMare</last_name>
      <phone>808-545-8548</phone>
    </contact>
    <investigator>
      <last_name>Paul A. DeMare</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Cancer Center of Hawaii-Liliha</name>
      <address>
        <city>Honolulu</city>
        <state>Hawaii</state>
        <zip>96817</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paul A. DeMare</last_name>
      <phone>808-545-8548</phone>
    </contact>
    <investigator>
      <last_name>Paul A. DeMare</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jyoti D. Patel</last_name>
      <phone>312-695-1301</phone>
      <email>cancer@northwestern.edu</email>
    </contact>
    <investigator>
      <last_name>Jyoti D. Patel</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Harold Alfond Center for Cancer Care</name>
      <address>
        <city>Augusta</city>
        <state>Maine</state>
        <zip>04330</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas H. Openshaw</last_name>
      <phone>207-973-4274</phone>
    </contact>
    <investigator>
      <last_name>Thomas H. Openshaw</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Maine Medical Center- Scarborough Campus</name>
      <address>
        <city>Scarborough</city>
        <state>Maine</state>
        <zip>04074</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ian J. Bristol</last_name>
      <phone>207-396-8090</phone>
      <email>wrighd@mmc.org</email>
    </contact>
    <investigator>
      <last_name>Ian J. Bristol</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sinai Hospital of Baltimore</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeanette A. Linder</last_name>
      <phone>410-601-6120</phone>
      <email>pridgely@lifebridgehealth.org</email>
    </contact>
    <investigator>
      <last_name>Jeanette A. Linder</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Lahey Hospital and Medical Center</name>
      <address>
        <city>Burlington</city>
        <state>Massachusetts</state>
        <zip>01805</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jacob M. Sands</last_name>
      <phone>781-744-8027</phone>
    </contact>
    <investigator>
      <last_name>Jacob M. Sands</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Saint Joseph Mercy Hospital</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48106-0995</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Samir Narayan</last_name>
      <phone>734-712-3456</phone>
    </contact>
    <investigator>
      <last_name>Samir Narayan</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oakwood Hospital</name>
      <address>
        <city>Dearborn</city>
        <state>Michigan</state>
        <zip>48124</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Samir Narayan</last_name>
      <phone>734-712-3456</phone>
    </contact>
    <investigator>
      <last_name>Samir Narayan</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>West Michigan Cancer Center</name>
      <address>
        <city>Kalamazoo</city>
        <state>Michigan</state>
        <zip>49007</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Raymond S. Lord</last_name>
      <phone>269-373-7458</phone>
    </contact>
    <investigator>
      <last_name>Raymond S. Lord</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ramaswamy Govindan</last_name>
      <phone>800-600-3606</phone>
      <email>info@siteman.wustl.edu</email>
    </contact>
    <investigator>
      <last_name>Ramaswamy Govindan</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Barnes-Jewish West County Hospital</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63141</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ramaswamy Govindan</last_name>
      <phone>800-600-3606</phone>
      <email>info@siteman.wustl.edu</email>
    </contact>
    <investigator>
      <last_name>Ramaswamy Govindan</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Saint John's Mercy Medical Center</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63141</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jay W. Carlson</last_name>
      <phone>800-821-7532</phone>
      <email>sherrijr@iora.org</email>
    </contact>
    <investigator>
      <last_name>Jay W. Carlson</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CoxHealth South Hospital</name>
      <address>
        <city>Springfield</city>
        <state>Missouri</state>
        <zip>65807</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Nebraska Methodist Hospital</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tien-Shew W. Huang</last_name>
      <phone>402-354-5144</phone>
    </contact>
    <investigator>
      <last_name>Tien-Shew W. Huang</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of New Mexico</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Martin J. Edelman</last_name>
      <phone>505-272-6972</phone>
    </contact>
    <investigator>
      <last_name>Martin J. Edelman</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Beth Israel Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10003</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Benjamin P. Levy</last_name>
      <phone>212-367-1729</phone>
    </contact>
    <investigator>
      <last_name>Benjamin P. Levy</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Rochester</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yuhchyau Chen</last_name>
      <phone>585-275-5830</phone>
    </contact>
    <investigator>
      <last_name>Yuhchyau Chen</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Summa Akron City Hospital/Cooper Cancer Center</name>
      <address>
        <city>Akron</city>
        <state>Ohio</state>
        <zip>44304</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Charles A. Kunos</last_name>
      <phone>330-375-6101</phone>
    </contact>
    <investigator>
      <last_name>Charles A. Kunos</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Summa Barberton Hospital</name>
      <address>
        <city>Barberton</city>
        <state>Ohio</state>
        <zip>44203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Charles A. Kunos</last_name>
      <phone>330-375-6101</phone>
    </contact>
    <investigator>
      <last_name>Charles A. Kunos</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ohio State University Medical Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Meng X. Welliver</last_name>
      <phone>866-627-7616</phone>
      <email>osu@emergingmed.com</email>
    </contact>
    <investigator>
      <last_name>Meng X. Welliver</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Oklahoma Health Sciences Center</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Terence S. Herman</last_name>
      <phone>405-271-4272</phone>
      <email>julie-traylor@ouhsc.edu</email>
    </contact>
    <investigator>
      <last_name>Terence S. Herman</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Natalie Warren Bryant Cancer Center at Saint Francis</name>
      <address>
        <city>Tulsa</city>
        <state>Oklahoma</state>
        <zip>74136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Charles E. Stewart</last_name>
      <phone>918-494-2200</phone>
    </contact>
    <investigator>
      <last_name>Charles E. Stewart</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Legacy Mount Hood Medical Center</name>
      <address>
        <city>Gresham</city>
        <state>Oregon</state>
        <zip>97030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrew Y. Kee</last_name>
      <phone>507-538-7623</phone>
    </contact>
    <investigator>
      <last_name>Andrew Y. Kee</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Legacy Good Samaritan Hospital and Medical Center</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrew Y. Kee</last_name>
      <phone>507-538-7623</phone>
    </contact>
    <investigator>
      <last_name>Andrew Y. Kee</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Bryn Mawr Hospital</name>
      <address>
        <city>Bryn Mawr</city>
        <state>Pennsylvania</state>
        <zip>19010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Albert S. DeNittis</last_name>
      <phone>866-225-5654</phone>
    </contact>
    <investigator>
      <last_name>Albert S. DeNittis</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Paoli Memorial Hospital</name>
      <address>
        <city>Paoli</city>
        <state>Pennsylvania</state>
        <zip>19301</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Albert S. DeNittis</last_name>
      <phone>866-225-5654</phone>
    </contact>
    <investigator>
      <last_name>Albert S. DeNittis</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Radiation Therapy Oncology Group</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ramaswamy Govindan</last_name>
      <phone>314-362-5737</phone>
      <email>rgovinda@dom.wustl.edu</email>
    </contact>
    <investigator>
      <last_name>Ramaswamy Govindan</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Lankenau Hospital</name>
      <address>
        <city>Wynnewood</city>
        <state>Pennsylvania</state>
        <zip>19096</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Albert S. DeNittis</last_name>
      <phone>866-225-5654</phone>
    </contact>
    <investigator>
      <last_name>Albert S. DeNittis</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carol A. Sherman</last_name>
      <phone>843-792-9321</phone>
    </contact>
    <investigator>
      <last_name>Carol A. Sherman</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Texas Southwestern Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hak Choy</last_name>
      <phone>214-648-7097</phone>
    </contact>
    <investigator>
      <last_name>Hak Choy</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>M D Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anne S. Tsao</last_name>
      <phone>713-792-3245</phone>
    </contact>
    <investigator>
      <last_name>Anne S. Tsao</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Intermountain Medical Center</name>
      <address>
        <city>Murray</city>
        <state>Utah</state>
        <zip>84157</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>George M. Cannon</last_name>
      <phone>801-507-3950</phone>
    </contact>
    <investigator>
      <last_name>George M. Cannon</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Saint Mary's Hospital</name>
      <address>
        <city>Green Bay</city>
        <state>Wisconsin</state>
        <zip>54303</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>James L. Leenstra</last_name>
      <phone>920-433-8889</phone>
    </contact>
    <investigator>
      <last_name>James L. Leenstra</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Saint Vincent Hospital</name>
      <address>
        <city>Green Bay</city>
        <state>Wisconsin</state>
        <zip>54301</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>James L. Leenstra</last_name>
      <phone>920-433-8889</phone>
    </contact>
    <investigator>
      <last_name>James L. Leenstra</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Columbia Saint Mary's Hospital - Ozaukee</name>
      <address>
        <city>Mequon</city>
        <state>Wisconsin</state>
        <zip>53097</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Craig A. Schulz</last_name>
      <phone>414-326-2675</phone>
      <email>clinicaltrials@columbia-stmarys.org</email>
    </contact>
    <investigator>
      <last_name>Craig A. Schulz</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Columbia Saint Mary's Water Tower Medical Commons</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53211</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Craig A. Schulz</last_name>
      <phone>414-326-2675</phone>
      <email>clinicaltrials@columbia-stmarys.org</email>
    </contact>
    <investigator>
      <last_name>Craig A. Schulz</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Froedtert and the Medical College of Wisconsin</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elizabeth M. Gore</last_name>
      <phone>888-469-6614</phone>
    </contact>
    <investigator>
      <last_name>Elizabeth M. Gore</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Waukesha Memorial Hospital - ProHealth Care</name>
      <address>
        <city>Waukesha</city>
        <state>Wisconsin</state>
        <zip>53188</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wingate F. Clapper</last_name>
      <phone>262-928-7632</phone>
    </contact>
    <investigator>
      <last_name>Wingate F. Clapper</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>June 2, 2014</lastchanged_date>
  <firstreceived_date>April 1, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
    <mesh_term>Lung Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Etoposide phosphate</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Erlotinib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
